Ocugen
PA - MalvernBiotechnology
Focus: Ocugen is a biotechnology company focused on sight-threatening diseases, particularly in ophthalmology and infectious disease therapeutic areas. The company operates as a mid-cap biotech with a diversified pipeline of novel therapeutics targeting retinal dystrophies and ocular inflammation.
Profile data last refreshed 17h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Ocugen
AI assessmentNot HiringNo open roles listed right now. Follow Ocugen to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
OCU400
Retinitis PigmentosaClinical Trials (1)
NCT06574997Expanded Access Program for RP in Adults
N/AHelp build intelligence for Ocugen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.